← All trials
NCT05851781
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Jul 30, 2023
- Completion date
- Aug 30, 2023
- First posted
- May 10, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kafrelsheikh UniversityLead sponsor
- Kafrelsheikh UniversityOverall official - principal investigator
- Kafrelsheikh UniversityReponsible party - principal investigator
- Kafrelsheikh UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.